top of page
Katharina_Sahm.JPG

Dr. Katharina Sahm

Department of Neurology, University Medical Center Mannheim

European Center for Angioscience, Medical Faculty Mannheim

CCU Neuroimmunology and Brain Tumor Immunology,

German Cancer Research Center, Heidelberg

 

katharina.sahm(at)umm.de

Katharina Sahm attended the Medical Schools at the Universities Heidelberg and London. She obtained her MD at the Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology at the German Cancer Research Center and Department in Heidelberg under the supervision of Michael Platten. Currently, she is a Research Associate and Resident in Neurology at the Medical Faculty Mannheim and the Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology at the DKFZ in Heidelberg.

Qualifications and Scientific Curriculum

2004-2011

2014

2012-2018

since 2018

Medical School, Universities of Heidelberg and London

MD, Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center and Department of Neurooncology, University Hospital Heidelberg, Germany

Resident in Neurology, University Hospital Heidelberg and Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, Heidelberg

Research Associate and Resident in Neurology, Medical Faculty Mannheim, Heidelberg University and Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, Heidelberg, Germany

Selected publications

  1. Sahm K, Kessler T, Eisele P, Ratliff M, Sperk E, König L, Breckwoldt MO, Seliger C, Mildenberger I, Schrimpf D, Herold-Mende C, Zeiner PS, Tabatabai G, Meuth SG, Capper D, Bendzus M, von Deimling A, Wick W, Sahm F, Platten M: Concurrent gliomas in patients with multiple sclerosis. In prep. (Will be uploaded to pre-print server by date of full proposal submission)

  2. Abu Hejleh AP, Huck K, Jähne K, Epping L, Sonner JK, Meuth SG, Opitz C, Herold-Mende C, Sahm F, Platten M, Sahm K: Endothelial IDO is not involved in regulated antitumor immunity in the CNS. In prep. (Will be uploaded to pre-print server by date of full proposal submission)

  3. Zhang X-W, Huck K, Jähne K, Cichon F, Sonner JK, Ufer F, Bauer S, Woo MS, Green E, Lu K, Kilian M, Friese MA, Platten M, Sahm K: Activity-regulated cytoskeleton-associated protein/activity-regulated gene 3.1 (Arc/Arg3.1) enhances dendritic cell vaccination in experimental melanoma. Onco-immunology. 10:1920739, 2021.

  4. Kessler T, Berberich A, Casalini B, Drüschler K, Ostermann H, Dormann A, Walter S, Hai L, Schlesner M, Herold-Mende C, Jungk C, Unterberg A, Bendszus M, Sahm K, von Deimling A, Winkler F, Platten M, Wick W, Sahm F, Wick A: Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma. Neurooncol Adv. 2:vdz060, 2020.

  5. Anssar TM, Leitzmann MF, Linker RA, Meier C, Becker C, Jick S, Sahm K, Platten M, Hau P, Seliger C: Autoimmune diseases and immunosuppressive therapy in relation to the risk of glioma. Cancer Med. 9:1263-1275, 2020.

  6. Deumelandt K, Platten M, Ochs K: Synergy of vaccination and agonist OX40 treatment-toward a mechanism-driven combination of glioma immunotherapy. Neuro Oncol. 20:4-5, 2018.

  7. Ochs K, Ott M, Bunse T, Sahm F, Bunse L, Deumelandt K, Sonner JK, Keil M, von Deimling A, Wick W, Platten M: K27M-mutant histone-3 as a novel target for glioma immunotherapy. Oncoimmunology. 6:e1328340, 2017.

  8. Breckwoldt MO, Bode J, Kurz FT, Hoffmann A, Ochs K, Ott M, Deumelandt K, Krüwel T, Schwarz D, Fischer M, Helluy X, Milford D, Kirschbaum K, Solecki G, Chiblak S, Abdollahi A, Winkler F, Wick W, Platten M, Heiland S, Bendszus M, Tews B: Correlated magnetic resonance imaging and ultramicroscopy (MR-UM) is a tool kit to assess the dynamics of glioma angiogenesis. eLife. 5:e11712, 2016.

  9. Ochs K, Ott M, Rauschenbach KJ, Deumelandt K, Sahm F, Opitz CA, von Deimling A, Wick W, Platten M: Tryptophan-2,3-dioxygenase is regulated by prostaglandin E2 in malignant glioma via a positive signaling loop involving prostaglandin E receptor-4. J Neurochem. 136:1142-1154, 2015.

  10. Ochs K, Sahm F, Opitz CA, Lanz TV, Oezen I, Couraud PO, von Deimling A, Wick W, Platten M: Immature mesenchymal stem cell-like pericytes as mediators of immunosuppression in human malignant glioma. J Neuroimmunol. 265:106-16, 2013.




     

bottom of page